302 related articles for article (PubMed ID: 34922323)
1. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
Liu Z; Guo C; Dang Q; Wang L; Liu L; Weng S; Xu H; Lu T; Sun Z; Han X
EBioMedicine; 2022 Jan; 75():103750. PubMed ID: 34922323
[TBL] [Abstract][Full Text] [Related]
2. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer.
Liu Z; Liu L; Weng S; Guo C; Dang Q; Xu H; Wang L; Lu T; Zhang Y; Sun Z; Han X
Nat Commun; 2022 Feb; 13(1):816. PubMed ID: 35145098
[TBL] [Abstract][Full Text] [Related]
3. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
5. Identification of a ferroptosis-related gene signature predicting recurrence in stage II/III colorectal cancer based on machine learning algorithms.
Wang Z; Ma C; Teng Q; Man J; Zhang X; Liu X; Zhang T; Chong W; Chen H; Lu M
Front Pharmacol; 2023; 14():1260697. PubMed ID: 37711170
[No Abstract] [Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
8. Discovery of a novel six-long non-coding RNA signature predicting survival of colorectal cancer patients.
Fan Q; Liu B
J Cell Biochem; 2018 Apr; 119(4):3574-3585. PubMed ID: 29227531
[TBL] [Abstract][Full Text] [Related]
9. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
[TBL] [Abstract][Full Text] [Related]
10. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of long noncoding RNA SNHG15 correlates with liver metastasis and poor survival in colorectal cancer.
Huang L; Lin H; Kang L; Huang P; Huang J; Cai J; Xian Z; Zhu P; Huang M; Wang L; Xian CJ; Wang J; Dong J
J Cell Physiol; 2019 May; 234(5):7032-7039. PubMed ID: 30317592
[TBL] [Abstract][Full Text] [Related]
12. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
13. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
14. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
15. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer.
Li J; Wang W; Xia P; Wan L; Zhang L; Yu L; Wang L; Chen X; Xiao Y; Xu C
Int J Cancer; 2018 Nov; 143(9):2150-2160. PubMed ID: 29707762
[TBL] [Abstract][Full Text] [Related]
16. Exploring prognostic potential of long noncoding RNAs in colorectal cancer based on a competing endogenous RNA network.
Yang ZD; Kang H
World J Gastroenterol; 2020 Mar; 26(12):1298-1316. PubMed ID: 32256018
[TBL] [Abstract][Full Text] [Related]
17. Circulating lncRNA UCA1 and lncRNA PGM5-AS1 act as potential diagnostic biomarkers for early-stage colorectal cancer.
Wang M; Zhang Z; Pan D; Xin Z; Bu F; Zhang Y; Tian Q; Feng X
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212174
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer.
Lu Y; Wang W; Liu Z; Ma J; Zhou X; Fu W
Mol Med; 2021 Aug; 27(1):83. PubMed ID: 34344319
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of Six Autophagy-related Long Non-coding RNAs as Prognostic Signature in Colorectal Cancer.
Cheng L; Han T; Zhang Z; Yi P; Zhang C; Zhang S; Peng W
Int J Med Sci; 2021; 18(1):88-98. PubMed ID: 33390777
[TBL] [Abstract][Full Text] [Related]
20. CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer.
Ozawa T; Matsuyama T; Toiyama Y; Takahashi N; Ishikawa T; Uetake H; Yamada Y; Kusunoki M; Calin G; Goel A
Ann Oncol; 2017 Aug; 28(8):1882-1888. PubMed ID: 28838211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
